𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer

✍ Scribed by Rosario Vincenzo Iaffaioli; Anna Tortoriello; Gaetano Facchini; Michele Santangelo; Luigi Bucci; Landino Fei; Natale Martino; Giovanni Mantovani; Francesco Caponigro

Publisher
Springer US
Year
1995
Tongue
English
Weight
545 KB
Volume
35
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II trial of high dose epirubicin
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
✍ Kathy D. Miller; Nikhil Munshi; David Loesch; Lawrence H. Einhorn; George W. Sle πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 3 views

## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; HΓ¨ndrΓ© C. Falkson πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high